118 related articles for article (PubMed ID: 10362119)
1. Bcl-2 expression related to altered p53 protein and its impact on the progression of human pancreatic carcinoma.
Hu YX; Watanabe H; Ohtsubo K; Yamaguchi Y; Ha A; Motoo Y; Okai T; Sawabu N
Br J Cancer; 1999 Jun; 80(7):1075-9. PubMed ID: 10362119
[TBL] [Abstract][Full Text] [Related]
2. bcl-2 and p53 expression in resectable pancreatic adenocarcinomas: association with clinical outcome.
Sinicrope FA; Evans DB; Leach SD; Cleary KR; Fenoglio CJ; Lee JJ; Abbruzzese JL
Clin Cancer Res; 1996 Dec; 2(12):2015-22. PubMed ID: 9816161
[TBL] [Abstract][Full Text] [Related]
3. Immunohistochemical expression of bcl-2 in UICC stage I and III colorectal carcinoma patients: correlation with c-erbB-2, p53, ki-67, CD44, laminin and collagen IV in evaluating prognostic significance.
Zavrides H; Zizi-Sermpetzoglou A; Elemenoglou I; Papatheofanis I; Peros G; Athanasas G; Panousopoulos D
Pol J Pathol; 2006; 57(3):149-59. PubMed ID: 17219742
[TBL] [Abstract][Full Text] [Related]
4. Clinical contribution of bcl-2, p53 and Ki-67 proteins in pancreatic ductal adenocarcinoma.
Mäkinen K; Hakala T; Lipponen P; Alhava E; Eskelinen M
Anticancer Res; 1998; 18(1B):615-8. PubMed ID: 9568186
[TBL] [Abstract][Full Text] [Related]
5. Bax protein expression in colorectal cancer: association with p53, bcl-2 and patterns of relapse.
Giatromanolaki A; Sivridis E; Stathopoulos GP; Fountzilas G; Kalofonos HP; Tsamandas A; Vrettou E; Scopa C; Polychronidis A; Simopoulos K; Koukourakis MI
Anticancer Res; 2001; 21(1A):253-9. PubMed ID: 11299743
[TBL] [Abstract][Full Text] [Related]
6. Tumour suppressor protein (p53), apoptosis inhibiting protein (Bcl-2) and proliferating cell nuclear antigen (PCNA) expressions in a rat pancreatic tumour model.
Mäkinen K; Loimas S; Hakala T; Eskelinen M
Anticancer Res; 2007; 27(1A):23-6. PubMed ID: 17352211
[TBL] [Abstract][Full Text] [Related]
7. Reduced expression of BAX is associated with poor prognosis in patients with epithelial ovarian cancer: a multifactorial analysis of TP53, p21, BAX and BCL-2.
Schuyer M; van der Burg ME; Henzen-Logmans SC; Fieret JH; Klijn JG; Look MP; Foekens JA; Stoter G; Berns EM
Br J Cancer; 2001 Nov; 85(9):1359-67. PubMed ID: 11720475
[TBL] [Abstract][Full Text] [Related]
8. Association of Bcl-2 protein expression with gallbladder carcinoma differentiation and progression and its relation to apoptosis.
Mikami T; Yanagisawa N; Baba H; Koike M; Okayasu I
Cancer; 1999 Jan; 85(2):318-25. PubMed ID: 10023698
[TBL] [Abstract][Full Text] [Related]
9. Telomerase activity and Bcl-2 expression in non-small cell lung cancer.
Ohmura Y; Aoe M; Andou A; Shimizu N
Clin Cancer Res; 2000 Aug; 6(8):2980-7. PubMed ID: 10955774
[TBL] [Abstract][Full Text] [Related]
10. Apoptotic and mitotic indices predict survival rates in lymph node-negative colon carcinomas.
Sinicrope FA; Hart J; Hsu HA; Lemoine M; Michelassi F; Stephens LC
Clin Cancer Res; 1999 Jul; 5(7):1793-804. PubMed ID: 10430084
[TBL] [Abstract][Full Text] [Related]
11. Immunohistochemical expression of bcl-2 in Dukes' stage B and C colorectal carcinoma patients: correlation with p53 and ki-67 in evaluating prognostic significance.
Zavrides H; Zizi-Sermpetzoglou A; Elemenoglou I; Papatheofanis I; Peros G; Athanasas G; Panousopoulos D
Pol J Pathol; 2005; 56(4):179-85. PubMed ID: 16477877
[TBL] [Abstract][Full Text] [Related]
12. The possible role of p53 and bcl-2 expression in cervical carcinomas and their premalignant lesions.
Dimitrakakis C; Kymionis G; Diakomanolis E; Papaspyrou I; Rodolakis A; Arzimanoglou I; Leandros E; Michalas S
Gynecol Oncol; 2000 Apr; 77(1):129-36. PubMed ID: 10739702
[TBL] [Abstract][Full Text] [Related]
13. Interaction between bcl-2 and P53 in neoplastic progression of basal cell carcinoma of the head and neck.
Staibano S; Lo Muzio L; Pannone G; Scalvenzi M; Salvatore G; Errico ME; Fanali S; De Rosa G; Piattelli A
Anticancer Res; 2001; 21(6A):3757-64. PubMed ID: 11911244
[TBL] [Abstract][Full Text] [Related]
14. Expression of SGLT1, Bcl-2 and p53 in primary pancreatic cancer related to survival.
Casneuf VF; Fonteyne P; Van Damme N; Demetter P; Pauwels P; de Hemptinne B; De Vos M; Van de Wiele C; Peeters M
Cancer Invest; 2008 Oct; 26(8):852-9. PubMed ID: 18853313
[TBL] [Abstract][Full Text] [Related]
15. Expression of bcl-2, c-erbB-2, p53, and p21 (waf1-cip1) protein in thyroid carcinomas.
Soda G; Antonaci A; Bosco D; Nardoni S; Melis M
J Exp Clin Cancer Res; 1999 Sep; 18(3):363-7. PubMed ID: 10606183
[TBL] [Abstract][Full Text] [Related]
16. [Protein expression of p53, bcl-2, and bax in adenoid cystic carcinoma of lacrimal gland].
You JQ; Wang P
Zhonghua Yi Xue Za Zhi; 2008 Jul; 88(28):1978-82. PubMed ID: 19062739
[TBL] [Abstract][Full Text] [Related]
17. Molecular markers in gastric cancer: can p53 and bcl-2 protein expressions be used as prognostic factors?
Zafirellis K; Karameris A; Milingos N; Androulakis G
Anticancer Res; 2005; 25(5):3629-36. PubMed ID: 16101192
[TBL] [Abstract][Full Text] [Related]
18. Apoptotic index or a combination of Bax/Bcl-2 expression correlate with survival after resection of pancreatic adenocarcinoma.
Magistrelli P; Coppola R; Tonini G; Vincenzi B; Santini D; Borzomati D; Vecchio F; Valeri S; Castri F; Antinori A; Nuzzo G; Caraglia M; Picciocchi A
J Cell Biochem; 2006 Jan; 97(1):98-108. PubMed ID: 16173075
[TBL] [Abstract][Full Text] [Related]
19. p53 protein expression in intraductal papillary mucinous tumors (IPMT) of the pancreas as an indicator of tumor malignancy.
Kawahira H; Kobayashi S; Kaneko K; Asano T; Ochiai T
Hepatogastroenterology; 2000; 47(34):973-7. PubMed ID: 11020860
[TBL] [Abstract][Full Text] [Related]
20. Prognostic significance of p53, bcl-2 and Ki-67 in high risk superficial bladder cancer.
Stavropoulos NE; Filiadis I; Ioachim E; Hastazeris K; Tsimaris I; Kalogeras D; Stefanaki S; Agnantis NJ
Anticancer Res; 2002; 22(6B):3759-64. PubMed ID: 12552989
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
